Life Biosciences reports 4 dB vision gains in 2 of 3 glaucoma patients
Life Biosciences released the first human data for cellular reprogramming on 8 October 2026, and its own announcement puts a hard number on the result that most coverage described as a possible restoration of sight. In two of three participants, at least 28% of points in a visual field test improved by more than 4 decibels at Day 56. The Boston company’s release calls that a preliminary signal, not a restoration.
The therapy is ER-100, and the mechanism is unusual enough to matter. A single intravitreal injection delivers an AAV-2 vector carrying three transcription factors, OCT4, SOX2 and KLF4, known collectively as OSK. Those genes stay switched off until the patient takes daily oral doxycycline, which runs for eight weeks, or 56 days. An oral prednisolone taper runs alongside it to hold down inflammation from the immune response to the vector.
That steroid matters for how you read the safety result. Life Bio reported no dose-limiting toxicities, no adverse events of special interest and no serious adverse events through Day 56. It also reported that every adverse event that did occur was related to the procedure, the steroid or a pre-existing condition, and wasn’t directly associated with ER-100. So there were adverse events, and Business Insider’s account recorded only that none were major.
What the registry says that the release doesn’t
The trial is registered as NCT07290244, and the record fills in what a press release leaves out. It’s non-randomised, sequential and carries no masking at all, and the registry states plainly that results are compared to baseline. There’s no control group, so each participant is their own comparison. The Humphrey Visual Field measurement that produced the headline appears twice in the record, once as a safety outcome and once, further down, as a secondary efficacy one.
| Detail | As registered or announced |
|---|---|
| Participants dosed so far | 3, all with open angle glaucoma |
| Planned enrolment | Up to 18: 12 with glaucoma, 6 with NAION |
| Dose Level 1 | 2 x 1011 vector genomes per eye |
| Dose Level 2 | 6 x 1011 vector genomes per eye |
| Design | Open label, non-randomised, compared to baseline |
| Visual field signal | Over 4 dB at 28% or more of points, 2 of 3 participants, Day 56 |
| Age range | 40 to 85 |
| Trial start | 2 March 2026, recruiting at four US sites |
| Primary completion | May 2027 est., with follow-up to March 2032 est. |
An independent Data Safety Monitoring Board recommended moving to Dose Level 2, which is three times the first dose on the company’s own figures. Business Insider reported that threefold increase, and the release supplies the two numbers behind it. The trial is still running, and the release doesn’t say anyone has been dosed at the higher level yet.
While this Phase 1 study is designed to evaluate safety and tolerability, the preliminary observations of visual field improvements in two participants are encouraging as we continue to advance the ER-100 program.
Sharon Rosenzweig-Lipson, Chief Scientific Officer, Life Biosciences
The outside read was cautious in the same direction. Dr James Tsai, president of New York Eye and Ear Infirmary of Mount Sinai and a glaucoma specialist who wasn’t involved in the trial, told Business Insider the news is exciting but very preliminary. He said the therapy might have improved existing electrical signals in patients who still had some vision, rather than fully regenerating the eye. That’s the counter-reading a three-patient open-label readout can’t rule out, and the 4 dB bar it cleared is one Life Bio chose for its own presentation, which is the recurring trouble with any self-reported threshold.
The money is going to the companies that haven’t dosed anyone
Life Bio closed an $80 million Series D in April 2026, enough to fund operations into the second half of 2027. NewLimit, which hasn’t put a drug into a person yet, raised $435 million in June 2026 in a Series C led by Founders Fund. Its post names Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Eli Lilly Ventures and Nat Friedman and Daniel Gross among the backers, and says the company plans its first human trial of a liver reprogramming medicine, which Business Insider dates to 2027. That gap between capital and clinical stage is the sort of thing a round announcement tends to bury.
The science underneath it was published in 2020. The Nature paper Reprogramming to recover youthful epigenetic information and restore vision showed OSK expression reversing vision loss in a mouse model of glaucoma and in aged mice, and Life Bio in-licensed the intellectual property behind it. Moving that from mice to three people took until March 2026.
What’s worth watching is narrow and specific. Dose Level 2 starts with one sentinel participant, reviewed at 28 days before two more are dosed, at three times the vector. After the glaucoma escalation finishes, the registry says a dose gets selected for a cohort in NAION, a sudden optic neuropathy with no approved treatment. Life Bio’s registry entry runs follow-up out to 2032, so a durable answer on whether any of this holds is years away.
Get the daily rundown
One email each weekday with the AI news that matters, every claim linked to its primary source.
Free, one email each weekday, unsubscribe in one click. We never sell or share your address.
